Back to results
US 11,236,154 B2Granted
Carbohydrate antibodies, pharmaceutical compositions and uses thereof
AssigneeObi Pharma, Inc.
InventorsCheng-Der Tony Yu, Jiann-Shiun Lai, I-Ju Chen
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies or the antigen-binding portion thereof to a tumor-associate carbohydrate antigen. Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.
Claims17
A method for inhibiting proliferation of a cancer cell, comprising:
- contacting the cancer cell with an effective amount of an antibody, or antigen-binding portion thereof, that binds to a carbohydrate antigen, wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain variable region and a light chain variable region comprising:
- a heavy chain complementarity determining region HC-CDR1 selected from the group consisting of:
- (i) SEQ ID NO:
- 1,
- (ii) SEQ ID NO:
- 1 wherein amino acid residue 3 is substituted with an arginine (S028R), and
- (iii) SEQ ID NO:
- 1 wherein amino acid residue 6 is substituted with an arginine (T031R),
- a heavy chain complementarity determining region HC-CDR2 selected from the group consisting of:
- (i) SEQ ID NO:
- 2,
- (ii) SEQ ID NO:
- 2 wherein amino acid residue 6 is substituted with a glycine (D057G), and
- (iii) SEQ ID NO:
- 2 wherein amino acid residue 12 is substituted with a tyrosine (P063Y),
- a heavy chain complementarity determining region HC-CDR3 selected from the group consisting of:
- (i) SEQ ID NO:
- 3, and
- (ii) SEQ ID NO:
- 3 wherein amino acid residue 6 is substituted with an arginine (D105R),
- a light chain complementarity determining region LC-CDR1 selected from the group consisting of:
- (i) SEQ ID NO:
- 7,
- (ii) SEQ ID NO:
- 7 wherein amino acid residue 1 is substituted with a tryptophan (R024W), and
- (iii) SEQ ID NO:
- 7 wherein amino acid residue 9 is substituted with a glutamine (M032Q),
- a light chain complementarity determining region LC-CDR2 selected from the group consisting of:
- (i) SEQ ID NO:
- 8,
- (ii) SEQ ID NO:
- 8 wherein amino acid residue 1 is substituted with a glycine (A049G), and
- (iii) SEQ ID NO:
- 8 wherein amino acid residue 5 is substituted with a lysine (L053K), and
- a light chain complementarity determining region LC-CDR3 selected from the group consisting of:
- (i) SEQ ID NO:
- 9, and
- (ii) SEQ ID NO:
- 9 wherein amino acid residue 6 is substituted with an arginine (N093R),
- wherein the antibody, or an antigen-binding portion thereof comprises at least one of the amino acid substitutions in a CDR region selected from the group consisting of S028R, T031R, D057G, P063Y, D105R, R024W, M032Q, A049G, L053K and N093R.
37 more elements
A method for treating cancer, comprising:
- administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising:
- an antibody, or antigen-binding portion thereof, that binds to a carbohydrate antigen;
- and
- a pharmaceutical acceptable carrier,
- wherein the antibody, or antigen-binding portion thereof, comprises a heavy chain
- variable region and a light chain variable region comprising:
- a heavy chain complementarity determining region HC-CDR1 selected from the group consisting of:
- (i) SEQ ID NO:
- 1,
- (ii) SEQ ID NO:
- 1 wherein amino acid residue 3 is substituted with an arginine (S028R), and
- (iii) SEQ ID NO:
- 1 wherein amino acid residue 6 is substituted with an arginine (T031R),
- a heavy chain complementarity determining region HC-CDR2 selected from the group consisting of:
- (i) SEQ ID NO:
- 2,
- (ii) SEQ ID NO:
- 2 wherein amino acid residue 6 is substituted with a glycine (D057G), and
- (iii) SEQ ID NO:
- 2 wherein amino acid residue 12 is substituted with a tyrosine (P063Yl),
- a heavy chain complementarity determining region HC-CDR3 selected from the group consisting of:
- (i) SEQ ID NO:
- 3, and
- (ii) SEQ ID NO:
- 3 wherein amino acid residue 6 is substituted with an arginine (D105R),
- a light chain complementarity determining region LC-CDR1 selected from the group consisting of:
- (i) SEQ ID NO:
- 7,
- (ii) SEQ ID NO:
- 7 wherein amino acid residue 1 is substituted with a tryptophan (R024W), and
- (iii) SEQ ID NO:
- 7 wherein amino acid residue 9 is substituted with a glutamine (M032Q),
- a light chain complementarity determining region LC-CDR2 selected from the group consisting of:
- (i) SEQ ID NO:
- 8,
- (ii) SEQ ID NO:
- 8 wherein amino acid residue 1 is substituted with a glycine (A049G), and
- (iii) SEQ ID NO:
- 8 wherein amino acid residue 5 is substituted with a lysine (L053K), and
- a light chain complementarity determining region LC-CDR3 selected from the group consisting of:
- (i) SEQ ID NO:
- 9, and
- (ii) SEQ ID NO:
- 9 wherein amino acid residue 6 is substituted with an arginine (N093R),
- wherein the antibody, or an antigen-binding portion thereof, comprises at least one of the amino acid substitutions in a CDR region selected from the group consisting of S028R, T031R, D057G, P063Y, D105R, R024W, M032Q, A049G, L053K and N093R.
42 more elements
Dependencies are inferred from the claim text.